Skip to main content
Top
Published in: Clinical and Experimental Nephrology 4/2015

01-08-2015 | Original Article

Is the eGFR formula adequate for evaluating renal function before chemotherapy in patients with urogenital cancer? A suggestion for clinical application of eGFR formula

Authors: Jiro Uozumi, Mitsuru Noguchi, Yuji Tokuda, Shohei Tobu, Kazuma Udo, Hiroaki Kakinoki, Saya Kurata, Maki Nanri, Yuka Ichibagase, Kohei Takahara

Published in: Clinical and Experimental Nephrology | Issue 4/2015

Login to get access

Abstract

Background

Accurate evaluation of renal function is required before cancer chemotherapy. Various kinds of formula have been developed for estimating creatinine clearance (Ccr) or glomerular filtration rate (GFR) conveniently. We retrospectively examined the reliability of the GFR estimating formula using the renal function data in cancer chemotherapy.

Methods

Clinical data of 12 patients with urogenital cancer from 1998 to 2013 in Saga University Hospital were reviewed. Patients were treated with 6–21 (median 10.5) courses of chemotherapy and those patients underwent 9–29 (median 14.5) times of 24hrCcr tests before and during chemotherapy. We compared estimated GFR (eGFR) with 24hrCcr. In addition, we developed a novel method to estimate the Ccr using the patient-inherent 24hrCcr/eGFR ratio, which is calculated from initial 3 or 4 determinations of 24hrCcr and the corresponding eGFR. Those estimated Ccrs were also compared with 24hrCcr.

Results

The dissociation between 24hrCcr and eGFR was not constant, and a large dissociation was observed in some cases. The newly devised estimated Ccr demonstrated less dissociation from 24hrCcr compared with eGFR.

Conclusions

The eGFR formula is not adequate for the clinical use in cancer chemotherapy. The absolute value of eGFR is not reliable, but clinical use of eGFR as relative value seems to be acceptable. To avoid troublesome 24hrCcr measurement in long-term cancer chemotherapy, eGFR formula can be used for estimating Ccr in combination with the specific inherent 24hrCcr/eGFR ratio, which is obtained from 3 or 4 times of actual 24hrCcr measurements.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43:14–34.CrossRefPubMed Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43:14–34.CrossRefPubMed
2.
go back to reference Brunello A, Loaldi E, Balducci L. Dose adjustment and supportive care before and during treatment. Cancer Treat Rev. 2009;35:493–8.CrossRefPubMed Brunello A, Loaldi E, Balducci L. Dose adjustment and supportive care before and during treatment. Cancer Treat Rev. 2009;35:493–8.CrossRefPubMed
3.
go back to reference Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.CrossRefPubMed Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.CrossRefPubMed
4.
go back to reference Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461–70.CrossRefPubMed Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461–70.CrossRefPubMed
5.
go back to reference Levey AS, Greene T, Kusek JW, Beck GJ, Group MS. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:A0828 (Abstract). Levey AS, Greene T, Kusek JW, Beck GJ, Group MS. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:A0828 (Abstract).
6.
go back to reference Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed
7.
go back to reference Imai E, Izeki K, Nitta K, Fukagawa M, Yasuda Y, Yamagata K, Yokoyama H. Assessment of renal function for adult: in clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012. Jpn J Nephrol. 2012;54:1062–5 [in Japanese]. Imai E, Izeki K, Nitta K, Fukagawa M, Yasuda Y, Yamagata K, Yokoyama H. Assessment of renal function for adult: in clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012. Jpn J Nephrol. 2012;54:1062–5 [in Japanese].
8.
go back to reference Holweger K, Bokemeyer C, Lipp HP. Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge. J Cancer Res Clin Oncol. 2005;131:559–67.CrossRefPubMed Holweger K, Bokemeyer C, Lipp HP. Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge. J Cancer Res Clin Oncol. 2005;131:559–67.CrossRefPubMed
9.
go back to reference Barraclough LH, Field C, Wieringa G, Swindell R, Livsey JE, Davidson SE. Estimation of renal function—What is appropriate in cancer patients? Clin Oncol. 2008;20:721–6.CrossRef Barraclough LH, Field C, Wieringa G, Swindell R, Livsey JE, Davidson SE. Estimation of renal function—What is appropriate in cancer patients? Clin Oncol. 2008;20:721–6.CrossRef
10.
go back to reference Faluyi OO, Msinghe SP, Hayward RL, Clive S. Accuracy of GFR estimation by Cockroft and Gault, MDRD, and Wright equations in oncology patients with renal impairment. Med Oncol. 2012;29:755–60.CrossRefPubMed Faluyi OO, Msinghe SP, Hayward RL, Clive S. Accuracy of GFR estimation by Cockroft and Gault, MDRD, and Wright equations in oncology patients with renal impairment. Med Oncol. 2012;29:755–60.CrossRefPubMed
11.
go back to reference Aapro M, Launary-Vacher V. Importance of monitoring renal function in patients with cancer. Cancer Treat Rev. 2012;38:235–40.CrossRefPubMed Aapro M, Launary-Vacher V. Importance of monitoring renal function in patients with cancer. Cancer Treat Rev. 2012;38:235–40.CrossRefPubMed
12.
go back to reference Raj GV, Iasonos A, Herr H, Donat SM. Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J Clin Oncol. 2006;24:3095–100.CrossRefPubMed Raj GV, Iasonos A, Herr H, Donat SM. Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J Clin Oncol. 2006;24:3095–100.CrossRefPubMed
13.
go back to reference Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of cisplatin with the human organic cation transporter 2. Clin Cancer Res. 2008;14:3875–80.CrossRefPubMed Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of cisplatin with the human organic cation transporter 2. Clin Cancer Res. 2008;14:3875–80.CrossRefPubMed
14.
go back to reference Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1–3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006;319:879–86.CrossRefPubMed Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1–3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006;319:879–86.CrossRefPubMed
15.
go back to reference Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol. 2007;74:477–87.CrossRefPubMed Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol. 2007;74:477–87.CrossRefPubMed
16.
go back to reference Ciarimboli G, Lancaster CS, Schlatter E, Franke RM, Sprowl JA, Pavenstadt H, Massmann V, Guckel D, Mathijssen RHJ, Yang W, Pui CH, Relling MV, Herrmann E, Sparreboom A. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res. 2012;18:1101–8.PubMedCentralCrossRefPubMed Ciarimboli G, Lancaster CS, Schlatter E, Franke RM, Sprowl JA, Pavenstadt H, Massmann V, Guckel D, Mathijssen RHJ, Yang W, Pui CH, Relling MV, Herrmann E, Sparreboom A. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res. 2012;18:1101–8.PubMedCentralCrossRefPubMed
Metadata
Title
Is the eGFR formula adequate for evaluating renal function before chemotherapy in patients with urogenital cancer? A suggestion for clinical application of eGFR formula
Authors
Jiro Uozumi
Mitsuru Noguchi
Yuji Tokuda
Shohei Tobu
Kazuma Udo
Hiroaki Kakinoki
Saya Kurata
Maki Nanri
Yuka Ichibagase
Kohei Takahara
Publication date
01-08-2015
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 4/2015
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-014-1037-3

Other articles of this Issue 4/2015

Clinical and Experimental Nephrology 4/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.